+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Infant Oxygen Masks - Global Strategic Business Report

  • PDF Icon

    Report

  • 272 Pages
  • October 2026
  • Region: Global
  • Market Glass, Inc.
  • ID: 6098437
The global market for Infant Oxygen Masks was valued at US$886.9 Million in 2025 and is projected to reach US$1.2 Billion by 2032, growing at a CAGR of 4.0% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Infant Oxygen Masks Market - Key Trends & Drivers Summarized

Why Are Infant Oxygen Masks Vital in Neonatal and Pediatric Respiratory Support?

Infant oxygen masks are critical respiratory support devices specifically designed to deliver oxygen to newborns and infants with underdeveloped or compromised lungs. Unlike adult masks, they are tailored to fit the facial contours of infants to ensure comfort, safety, and optimal oxygen delivery without causing facial pressure or air leakage. These masks are commonly used in neonatal intensive care units (NICUs), pediatric wards, emergency settings, and home care environments, particularly for infants with respiratory distress syndrome (RDS), bronchopulmonary dysplasia, pneumonia, congenital heart conditions, or during post-surgical recovery.

The need for infant oxygen masks has grown in response to increasing rates of premature births, respiratory disorders in neonates, and congenital anomalies affecting pulmonary function. Globally, the burden of infant mortality related to inadequate respiratory care has driven governments and healthcare providers to scale up neonatal intensive care resources. In these contexts, infant oxygen masks serve as a frontline intervention - ensuring controlled and precise oxygen therapy while minimizing risk of oxygen toxicity, a serious concern in neonates. Their importance is further amplified by the role they play in emergency transport scenarios where timely oxygen delivery can be lifesaving.

What Innovations Are Improving the Design and Functionality of Infant Oxygen Masks?

Technological and design advancements are enhancing the safety, efficiency, and comfort of infant oxygen masks. Modern masks are increasingly made from hypoallergenic, medical-grade silicone or thermoplastic elastomers, which provide a better seal while being gentle on sensitive infant skin. Anti-asphyxiation features, soft padded rims, and adjustable elastic straps have been introduced to ensure a secure and comfortable fit during prolonged use. Innovations such as low dead space design help minimize rebreathing of CO2, crucial for infant respiratory management.

Another notable trend is the integration of oxygen concentration indicators and compatibility with humidified oxygen delivery systems, which are essential for maintaining mucosal integrity in neonates. Manufacturers are also producing masks in multiple sizes (preterm, neonate, infant) to improve patient-specific fitting and reduce the need for invasive procedures. Disposable oxygen masks, often used in infection-prone or emergency settings, are gaining popularity due to their safety and hygiene advantages. Furthermore, 3D modeling and digital manufacturing are enabling rapid prototyping of custom-fitted masks for infants with craniofacial abnormalities or long-term oxygen needs.

Which Regions and Healthcare Segments Are Driving Market Growth?

The demand for infant oxygen masks is highest in regions with growing investments in neonatal and pediatric care infrastructure. North America and Europe dominate the market due to their well-established NICU networks, strict regulatory oversight, and technological leadership in medical devices. The U.S., in particular, has seen expanded use of oxygen therapy in both hospital and home care settings for infants with chronic lung disease and congenital anomalies. Europe’s neonatal respiratory care market is supported by public healthcare funding and collaborative networks across tertiary hospitals.

Meanwhile, Asia-Pacific is the fastest-growing region, driven by high neonatal mortality rates, increasing awareness of pediatric respiratory health, and expansion of public health programs. Countries like India and China are investing heavily in maternal and infant care, leading to the rapid deployment of neonatal respiratory support equipment - including oxygen masks - in both urban and rural healthcare settings. Sub-Saharan Africa and parts of Latin America, though currently underpenetrated, present significant long-term opportunities, especially as NGOs and international donors fund improvements in neonatal care capacity and equipment availability in underserved areas.

The Growth in the Infant Oxygen Masks Market Is Driven by Several Factors

It is driven by the global rise in preterm births and respiratory disorders in neonates, which has increased demand for specialized respiratory support devices tailored for infants. Advances in neonatal care protocols and investments in NICU infrastructure worldwide are fueling adoption of infant oxygen masks as part of standardized oxygen therapy regimens. The market is also benefitting from the growth of pediatric home healthcare services, where non-invasive oxygen delivery systems are increasingly preferred for long-term treatment of chronic respiratory illnesses.

In addition, technological innovation in mask design - particularly improvements in material safety, comfort, and ergonomic fit - is making these devices more effective and user-friendly for both caregivers and healthcare professionals. Rising healthcare expenditure in developing economies, along with strong governmental and NGO-backed efforts to improve child health outcomes, is further expanding the addressable market. Regulatory focus on neonatal safety and the increasing availability of disposable and infection-resistant mask variants are also encouraging widespread adoption. Altogether, these factors are reinforcing the central role of infant oxygen masks in reducing neonatal respiratory morbidity and improving survival outcomes across global healthcare systems.

Report Scope

The report analyzes the Infant Oxygen Masks market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:
  • Segments: Type (With Operation Window, No Operation Window); Application (Hospitals, Other Applications)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the With Operation Window segment, which is expected to reach US$778.7 Million by 2032 with a CAGR of a 4.8%. The No Operation Window segment is also set to grow at 2.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $241.6 Million in 2025, and China, forecasted to grow at an impressive 7.1% CAGR to reach $241.2 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Infant Oxygen Masks Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Infant Oxygen Masks Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Infant Oxygen Masks Market expected to evolve by 2032?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2032?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AdvaCare Pharma, AMECO Technology, Artsana Group, Cardinal Health, Inc., Cathwide Medical and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Infant Oxygen Masks market report include:

  • AdvaCare Pharma
  • AMECO Technology
  • Artsana Group
  • Cardinal Health, Inc.
  • Cathwide Medical
  • Dispowell Surgicals
  • Drägerwerk AG & Co. KGaA
  • Fisher & Paykel Healthcare
  • GaleMed Corporation
  • International Biomedical
  • Laerdal Global Health
  • Maxtec
  • Medtronic plc
  • Neotech Products
  • Ningbo David Medical Device Co., Ltd.
  • Philips Respironics
  • Plasti-med
  • Smiths Medical
  • Teleflex Incorporated
  • Vapotherm Inc.

What Sets This Report Apart From Others?

  • Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
  • Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
  • Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
  • Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
  • Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
  • Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • World Market Trajectories
  • How Trump's Tariffs Impact the Market? The Big Question on Everyone's Mind
  • Infantile Spasm Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Diagnosis Rates and Early Intervention Efforts Throw the Spotlight on Infantile Spasm Therapeutics as a Critical Segment in Pediatric Neurology
  • Increasing Awareness Among Pediatricians and Neurologists Propels Demand for Timely and Evidence-Based Treatment Approaches
  • Here`s the Story: Clinical Guidelines Emphasizing Early Treatment Strengthen the Business Case for First-Line Therapeutics
  • Advances in Neuroimaging and EEG Technologies Drive Earlier and More Accurate Identification of Infantile Spasms
  • Growing Pipeline of ACTH Analogs, Steroids, and Antiepileptic Drugs Supports Innovation in Drug Formulations and Dosing Regimens
  • Here`s How Research in Genetic and Metabolic Causes of Infantile Spasms Is Opening Doors to Targeted Therapies
  • Rising Focus on Neurodevelopmental Outcomes Fuels Demand for Fast-Acting and Tolerable Therapeutic Options
  • Global Expansion of Pediatric Specialty Clinics Enhances Access to Infantile Spasm Treatment in Urban and Semi-Urban Areas
  • Growth in Specialty Pharmaceuticals and Orphan Drug Designation Accelerates R&D and Market Entry of Novel Therapeutics
  • Emergence of Precision Medicine and Genetic Screening Fuels Long-Term Potential for Personalized Infantile Spasm Therapies
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Infantile Spasm Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • Table 2: World Recent Past, Current & Future Analysis for Infantile Spasm Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 3: World Historic Review for Infantile Spasm Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 4: World 13-Year Perspective for Infantile Spasm Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • Table 5: World Recent Past, Current & Future Analysis for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 6: World Historic Review for Anticonvulsants by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 7: World 13-Year Perspective for Anticonvulsants by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 10: World 13-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 11: World Recent Past, Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 12: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 13: World 13-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 14: World Recent Past, Current & Future Analysis for Vigabatrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 15: World Historic Review for Vigabatrin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 16: World 13-Year Perspective for Vigabatrin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 17: World Recent Past, Current & Future Analysis for Adrenocorticotropic Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 18: World Historic Review for Adrenocorticotropic Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 19: World 13-Year Perspective for Adrenocorticotropic Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 20: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 21: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 22: World 13-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 23: World Recent Past, Current & Future Analysis for Solid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 24: World Historic Review for Solid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 25: World 13-Year Perspective for Solid Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • Table 26: World Recent Past, Current & Future Analysis for Liquid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • Table 27: World Historic Review for Liquid Dosage by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • Table 28: World 13-Year Perspective for Liquid Dosage by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
III. MARKET ANALYSIS
UNITED STATES
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
CANADA
JAPAN
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
CHINA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
EUROPE
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
FRANCE
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
GERMANY
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
ITALY
UNITED KINGDOM
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
AUSTRALIA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
INDIA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Infantile Spasm Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AdvaCare Pharma
  • AMECO Technology
  • Artsana Group
  • Cardinal Health, Inc.
  • Cathwide Medical
  • Dispowell Surgicals
  • Drägerwerk AG & Co. KGaA
  • Fisher & Paykel Healthcare
  • GaleMed Corporation
  • International Biomedical
  • Laerdal Global Health
  • Maxtec
  • Medtronic plc
  • Neotech Products
  • Ningbo David Medical Device Co., Ltd.
  • Philips Respironics
  • Plasti-med
  • Smiths Medical
  • Teleflex Incorporated
  • Vapotherm Inc.

Table Information